rhCG
Phase 1Small molecule
rhCG is one of 28 small molecule programs targeting Hyperandrogenism. It is currently in Phase 1.
2
Indications
6
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
30 competitors in Adolescent
#DrugCompanyPhaseTrials
1Zoloft
VViatris Specialty LLC
Approved
Abilify
OtsukaApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Cymbalta
Jazz PharmaceuticalsPhase 2
Brintellix
TakedaPhase 2
Sunlenca
GileadPhase 2
Camptosar
PfizerPhase 2
Valdoxan
NovartisPhase 3
Zyprexa
MMODAG GmbH
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Effectiveness1 trial
Ovulation Induction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhCG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Virginia